摘要
目的探讨miRNA-34a、miRNA-34c、miRNA-135a在轻度认知障碍（MCI）及阿尔茨海默病（AD）早期诊断中的应用价值。方法以2014年8月至2016年5月就诊于深圳市第二人民医院门诊或住院部的患者为研究对象，使用定量PCR法检测AD患者、MCI患者及正常对照组血清miRNA-34a、miRNA-34c、miRNA-135a水平并进行组间比较。结果AD组患者血清miRNA-34a水平略高于对照组（P=0．042）；MCI组、AD组患者血清miRNA-34c水平高于对照组（P〈0．05）；MCI组、AD组患者血清miRNA-135a水平均低于对照组，且AD组患者低于MCI组（P〈0．05）。结论血清miRNA34c及miRNA-135a有望成为MCI及AD早期诊断的生物标志物。
Objective To investigate the clinical value of miRNA-34a, miRNA-34c, and miRNA- 135a in the early diagnosis of mild cognitive impairment （MCI） and Alzheimerg disease （AD）. Methods The patients were collected in the outpatient and inpatient of Neurology during Aug 2014 to May 2016. The levels of miRNA-34a, miRNA-34c, an dmiRNA-135a were detected with quantitative real-time poly- merase chain reaction （qRT-PCR）. Results AD patients had higher level of miRNA-34a than the con- trols. The levels of miRNA-34c were higher in MCI and AD patients, while lower levels of miRNA-135a compared to the controls. Conclusions The miRNA 34a and miRNA-135a were likely to became the bio- marker in early diagnosis of MCI and AD.
出处
《中国医师杂志》
CAS
2017年第5期683-686,共4页
Journal of Chinese Physician
基金
深圳市科技创新委员会深圳市科技研发资金知识创新计划（JCYJ20140415090443270）
